Compare RGEN & IBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RGEN | IBRX |
|---|---|---|
| Founded | 1981 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.0B | 8.2B |
| IPO Year | 1995 | 2015 |
| Metric | RGEN | IBRX |
|---|---|---|
| Price | $177.23 | $9.18 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 22 | 4 |
| Target Price | ★ $189.70 | $12.75 |
| AVG Volume (30 Days) | 880.1K | ★ 8.8M |
| Earning Date | 10-27-2026 | 11-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 286.96 | 38.71 |
| EPS | ★ 0.24 | N/A |
| Revenue | ★ $141,236,000.00 | $113,288,000.00 |
| Revenue This Year | $12.04 | $99.26 |
| Revenue Next Year | $17.80 | $95.57 |
| P/E Ratio | $805.46 | ★ N/A |
| Revenue Growth | 35.10 | ★ 668.31 |
| 52 Week Low | $100.99 | $1.95 |
| 52 Week High | $198.87 | $12.43 |
| Indicator | RGEN | IBRX |
|---|---|---|
| Relative Strength Index (RSI) | 63.35 | 64.16 |
| Support Level | $159.22 | $6.68 |
| Resistance Level | N/A | $9.54 |
| Average True Range (ATR) | 6.58 | 0.51 |
| MACD | 0.98 | 0.06 |
| Stochastic Oscillator | 75.63 | 90.41 |
Repligen, headquartered in Waltham, Massachusetts, is a global life sciences company that develops and sells bioprocessing equipment and supplies used in the manufacturing of biologic drugs, including monoclonal antibodies, recombinant proteins, vaccines, and cell and gene therapies. Its customers include biopharmaceutical companies, contract development and manufacturing organizations, and other life science companies. It sells four main product categories: filtration and fluid management is the largest category (about 55% of total revenue), while chromatography, proteins, and process analytics are 21%, 11%, and 13%, respectively. Customers in North America, Europe, and Asia-Pacific contribute about 44%, 37%, and 19% of revenue, respectively.
ImmunityBio Inc is a biotechnology company focused on developing and commercializing next-generation immunotherapies designed to activate the patient's immune system and provide durable protection against cancer and infectious diseases. Its approach harnesses both the adaptive and innate immune systems with the Cancer BioShield platform. The platform is built around the proprietary IL-15 superagonist ANKTIVA (nogapendekin alfa inbakicept) and is supported by a portfolio that includes adenovirus-vectored vaccines, NK-cell therapies, and additional immunomodulators. The company operates in the United States and Europe, with the majority of its revenue coming from the United States.